Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

C&D financials

This article was originally published in The Tan Sheet

Executive Summary

First quarter oral care sales rise in mid-single digits on growth in "below radar" accounts such as club and dollar stores, as well as heavy pipeline volume for Arm & Hammer Complete Care toothpaste, Church & Dwight reports May 5. Sales in antiperspirant business were "essentially flat," but earnings improved due to sell-in of new items and manufacturing synergies for the Arrid brand, firm says. Personal care sales, including Armkel and affiliates, rose 5% to $94.7 mil. spurred by oral care, skin care categories. Overall C&D sales fell 3.3% to $248.3 mil., reflecting rationalization of the former Carter-Wallace pet care and USA Detergents product lines. Net income grew 40.4% to $20.9 mil. due primarily to an accounting charge in the year-ago period. Adjusting for the charge, EPS increased 19%...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095438

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel